Trial Profile

Short Chemo Radio Immunotherapy in Follicular Lymphoma Trial of Y-90 ibritumomab tiuxetan (Zevalin®) as therapy for first and second relapse in follicular lymphoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Ibritumomab tiuxetan; Prednisolone; Vincristine
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms SCHRIFT

Most Recent Events

16 Dec 2021 Status changed to discontinued.
30 Aug 2014 According to United Kingdom Clinical Research Network record the accruel to date is 90%
30 Jan 2014 According to UKCRN the accruel to date is 90%

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com